PRAXIS PRECISION MEDICINES INC
NASDAQ: PRAX (Praxis Precision Medicines, Inc)
Last update: 15 hours ago40.24
2.18 (5.73%)
| Previous Close | 38.06 |
| Open | 38.76 |
| Volume | 511,850 |
| Avg. Volume (3M) | 551,569 |
| Market Cap | 811,367,232 |
| Price / Sales | 79.68 |
| Price / Book | 1.72 |
| 52 Weeks Range | |
| Earnings Date | 2 May 2025 |
| Operating Margin (TTM) | -856.97% |
| Diluted EPS (TTM) | -10.21 |
| Quarterly Revenue Growth (YOY) | 1,349.10% |
| Total Debt/Equity (MRQ) | 0.31% |
| Current Ratio (MRQ) | 10.77 |
| Operating Cash Flow (TTM) | -131.76 M |
| Levered Free Cash Flow (TTM) | -69.94 M |
| Return on Assets (TTM) | -43.81% |
| Return on Equity (TTM) | -70.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Praxis Precision Medicines, Inc | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.25 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.46% |
| % Held by Institutions | 110.91% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cormorant Asset Management, Lp | 31 Dec 2024 | 1,693,219 |
| Perceptive Advisors Llc | 31 Dec 2024 | 1,329,735 |
| Ra Capital Management, L.P. | 31 Dec 2024 | 761,955 |
| Verition Fund Management Llc | 31 Dec 2024 | 464,508 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 111.00 (Deutsche Bank, 175.85%) | Buy |
| Median | 85.00 (111.23%) | |
| Low | 73.00 (Baird, 81.41%) | Buy |
| Average | 91.80 (128.13%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 43.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 May 2025 | 105.00 (160.93%) | Buy | 38.06 |
| 03 Mar 2025 | 105.00 (160.93%) | Buy | 33.55 | |
| Needham | 08 Apr 2025 | 85.00 (111.23%) | Buy | 28.60 |
| 03 Mar 2025 | 85.00 (111.23%) | Buy | 33.55 | |
| Baird | 03 Mar 2025 | 73.00 (81.41%) | Buy | 33.55 |
| Truist Securities | 03 Mar 2025 | 85.00 (111.23%) | Buy | 33.55 |
| Deutsche Bank | 11 Feb 2025 | 111.00 (175.84%) | Buy | 84.24 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |